CPT 80053 is referenced in 12 tracked payer policy changes from Healthfirst, Independence Blue Cross, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 80053 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Effective July 1, 2026, Healthfirst will no longer reimburse CPT code 80050 (General Health Panel) across all lines of business, aligning with CMS and NYS Medicaid non-coverage determinations. All claims submitted with this code will be denied. Providers may bill individual component codes (80053, 85025, 85027, 85004, 85007, 85009, 84443) separately if medically necessary and properly documented.
Independence Blue Cross updated policy 00.01.61b effective February 1, 2026, to change reimbursement methodology for laboratory panels. When multiple component tests from the same panel are billed on the same date by the same provider/group for the same member, the insurer will reimburse only the comprehensive panel code instead of individual component codes. This affects 11 comprehensive panels including metabolic, hepatic, lipid, renal, obstetric, and STI testing panels.
Independence Blue Cross updated policy 00.01.61b to change reimbursement methodology for Sexually Transmitted Infection (STI) component laboratory tests effective 02/01/2026. When two or more STI component tests are reported on the same date by the same provider for the same member, reimbursement will be made for the individual, more comprehensive code (CPT 87801) rather than separate component codes. This bundling requirement aligns with CMS NCCI guidelines and applies to 11 comprehensive laboratory panels.
Maryland Medicaid FFS updated its policy on billing ancillary services (labs, imaging, dialysis, respiratory services, EKG) during Administrative Days. Medical/surgical supplies are no longer covered on Administrative Days as costs are incorporated into the base rate. Hospitals must document medical necessity, complete the MDH 1288 form with placement activities, and request retrospective UCA review. Revenue codes for BMP and CMP have been updated to 0301.
Ambetter from Arizona Complete Health is discontinuing coverage under HCPCS bundled code 80050 effective 10/01/2025. The four component tests (Comprehensive Metabolic Panel, Complete Blood Count, and Thyroid Stimulating Hormone) must now be billed individually using their respective codes. All submissions of bundled code 80050 after 09/30/2025 will receive automatic denials with explanation code 46.
Point32Health issued a metabolic monitoring policy for patients on antipsychotic medications, emphasizing annual screening for diabetes and cholesterol levels. The policy provides approved CPT codes for billing glucose, HbA1c, LDL-C, and other cholesterol tests, and requires providers to document baseline metabolic testing at discharge and coordinate care across behavioral health, primary care, and prescribing providers.
Point32Health issued new guidance requiring annual metabolic monitoring (glucose, HbA1c, and cholesterol testing) for all patients on antipsychotic medications across all age groups. Billing teams must use specific approved CPT codes for these screenings and ensure proper documentation, especially for inpatient psychiatric discharges. This policy emphasizes care coordination among providers and includes a referral pathway for Tufts Health Together SMI members.
Independence Blue Cross updated MA01.006b effective 02/01/2026 to change reimbursement methodology for Sexually Transmitted Infection (STI) component laboratory tests. When two or more STI component tests are reported on the same date by the same provider for the same member, reimbursement will be made for the individual comprehensive code (CPT 87801) instead of separate component codes. This policy continues to apply to all listed comprehensive laboratory panels across comprehensive metabolic panels, hepatic panels, and other organ-specific panels.
Independence Blue Cross Medicare Advantage is changing how it reimburses STI (Sexually Transmitted Infection) component laboratory tests. Effective 02/01/2026, when two or more STI component tests are billed on the same date by the same provider for the same member, the claim will be reimbursed as a single comprehensive STI panel code (87801) instead of individual component codes. This requires billing teams to bundle related STI tests or expect claim denials and reprocessing.
Maryland Medicaid now allows billing of specific medically necessary ancillary services on Administrative Days, but medical/surgical supplies are no longer covered separately as their costs are now included in the base Administrative Day rate. Hospitals must use the updated MDH 1288 form and follow new revenue code guidelines for metabolic panels.
Aetna considers laboratory test panels experimental, investigational, or unproven when they include nonstandard tests that have no proven value. Panels are also considered experimental, investigational, or unproven when they include standard tests performed for persons without specific signs and symptoms warranting the test, or for indications that are not established. The policy names panels and tests from Aeron Life Cycles, Alletess Medical Laboratory, BioHealth, DiagnosTechs, Doctor's Data Lab, Great Plains Laboratory, Moleculera Labs, Physicians Lab and ZRT Laboratory as experimental, investigational, or unproven, and it lists other laboratories that perform non-standard panels considered experimental, investigational, or unproven. Certain tests are considered medically necessary in specific situations, such as urine porphyrins for persons with signs and symptoms of porphyria. There is no evidence that these laboratory test panels affect the management of afflicted individuals.
Aetna considers these services medically necessary for members with anorexia nervosa or bulimia nervosa: medical evaluation with history and physical examination, psychiatric or psychological consultation and testing, blood count and serum chemistry, albumin and prealbumin, liver function tests, electrocardiography, urinalysis, thyroid function testing (TSH), bone density measurement for evaluation of anorexic members, and LH, FSH and estradiol for women with amenorrhea or oligomenorrhea. Treatment considered medically necessary includes nutritional counseling, psychotherapy (such as cognitive behavioral therapy, dialectical behavior therapy, family-based, interpersonal and psychodynamic psychotherapy), and enteral nutrition as a last resort for the treatment of anorexia nervosa. Self-administered pharmacotherapies are managed under the pharmacy benefit. The policy lists CPT and HCPCS codes covered if selection criteria are met, and codes not covered for the indications listed. Aetna considers a long list of services experimental, investigational or unproven for anorexia nervosa, bulimia nervosa and binge-eating disorder, including brain imaging, EEG, routine screening of asymptomatic adolescents and adults for eating disorders, acupuncture, deep brain stimulation, electroconvulsive therapy, repetitive transcranial magnetic stimulation, cannabinoids, oxytocin and ghrelin agonists.
Watch 80053
Get one email when a payer policy names 80053, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 80053
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 80053 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.